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Developing standards for MS care 
Methods 
 A modified Delphi process was conducted, including both a core Delphi 
Consensus Panel and an additional Reviewing Group (Figure 1).
 Responses were collected via online surveys; the Panel remained anonymous to 
analysts and Chairs throughout.
Participants
 Four Chairs directed the process; they represented neurology, patient-reported 
outcomes, nursing/policy and the patient perspective.
 Participants were invited from regions where MS prevalence is high:4 North 
America, Northern Europe, Western Europe, Southern Europe, Eastern Europe  
and Russia, Australia and New Zealand, Middle East and North Africa.
In total, 41 MS neurologists from 22 countries were invited to participate in 
the Delphi Consensus Panel (Figure 1); 29 agreed to participate. 
Thirty-nine MS nurses, people with MS and allied healthcare professionals 
were invited to participate in the Reviewing Group to advise the Chairs; 
31 agreed to participate (Figure 1).
Figure 1. Modified Delphi process flow chart. 
Figure 3. Proposed MS Brain Health quality improvement cycle.
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Background
 Although broad guidelines exist for multiple sclerosis (MS) care,1,2 there is no 
benchmark for timely care. 
The need for prompt diagnosis and early treatment of MS was 
highlighted by the widely endorsed policy report Brain health: time 
matters in multiple sclerosis.3 
 The current study aimed to engage multiple stakeholder groups in defining 
standards for the timing of key steps in the MS care pathway. 
 These standards will inform the content of tools to help MS clinics strive for 
the highest level of care.
Conclusions
 An international group of MS neurologists, MS nurses, allied healthcare 
professionals and people with MS have been involved in a modified Delphi 
process to develop quality standards for MS care. 
 These quality standards describe the timings of key steps in the MS care 
pathway and will provide a new benchmark for MS clinics globally. 
 Tools will be developed to help multiple stakeholders improve care and  
deliver these standards in practice. 
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To read Brain health: time matters in multiple sclerosis, visit www.msbrainhealth.orgPresented at the 3rd annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 1–3, 2018, San Diego, CA, USA  
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Rounds 2 and 3 – timings
 In round 2, the Panel suggested timings for ‘core’, ‘achievable’ and ‘aspirational’ 
standards (Table 1) for each variable, by free text.
 In round 3, the Panel were shown box plots of the round 2 data and asked to 
choose timings from given options. 
 Consensus statements related to symptom onset, referral, diagnosis, treatment 
decisions, lifestyle, monitoring and managing new symptoms were developed 
based on these results. 
Round 1 – principles 
 We derived 21 time-related principles from the recommendations in the report 
Brain health: time matters in multiple sclerosis.3 
 The Panel were asked if each principle was ‘an appropriate and accurate 
description of a good standard when considering brain health in people  
with MS’ and were invited to suggest additional principles for inclusion.
 The Reviewing Group reviewed the results and provided feedback.
 Variables describing the principles in clinical practice were developed for round 2. 
Some principles identified were not considered time dependent; these were taken 
straight to round 4.
Table 1. Definitions used for consensus standards. 
Standard Definition
Core This should currently be achieved by most MS teams worldwide, regardless 
of the local healthcare system, and will provide a minimum standard
Achievable This is a realistic target for most MS teams and reflects a good standard 
of care
Aspirational This might be achieved by only a few MS teams, where the local healthcare 
system allows, but should set the standard for high-quality care
Figure 2. Subset of ‘achievable’ standards that gained at least 75% agreement from the Delphi Consensus Panel. 
DMT, disease-modifying therapy; MRI, magnetic resonance imaging
 Diagnosis
  2 weeks ■ The MS team should discuss the aims of treatment with each patient within 2 weeks of MS diagnosis
  3 weeks ■ The MS team should discuss the pros and cons of early treatment with a DMT with patients  within 3 weeks of diagnosis
   ■ The MS team should assess within 3 weeks of an MS diagnosis whether the patient is eligible for treatment with a
    suitable DMT
 Patient becomes eligible for DMT
  3 weeks ■ A DMT should be offered to a patient with MS within 3 weeks of their becoming eligible for one
 Patient decides to start DMT
  2 weeks ■ Treatment with a DMT should commence within 2 weeks of a patient with MS agreeing this approach with 
    their neurologist
  Every  ■ The MS team should review at least once every 6 months whether each patient with MS who is not receiving 
  6 months  a DMT is eligible for one, based on applicable guidelines 
 Routine consultations
  Every  ■ The MS team should perform a follow-up clinical evaluation of each patient at least once every 6 months
  6 months ■ The MS team should review with each patient at least once every 6 months the aims of their treatment for MS 
   ■ The MS team should review with each patient at least once every 6 months their currently prescribed DMT and consider  
    alternatives if appropriate
  Every 1 year ■ All patients with MS should be offered an MRI scan at least once every year
  Regularly ■ The MS team should regularly enter patient data into an MS database
 Suboptimal response to DMT
  4 weeks ■ If a patient’s response to their current DMT is judged to be suboptimal, an appropriate, alternative DMT should be  
    offered within 4 weeks
 New or worsened symptoms
  7 days ■ Patients with MS should report new or worsened symptoms to their MS team within 7 days of experiencing 
    these symptoms
 Reporting new or worsened symptoms
  2 days ■ The MS team should respond within 2 days to a patient with MS reporting an acute deterioration of symptoms
  3 days ■ Patients with MS who experience an acute deterioration of symptoms should be seen by the relevant member of their 
    MS team within 3 days of reporting these symptoms
Monitoring
New symptoms 
Treatment
decisions
 The predefined threshold for consensus was at least 75% agreement, with a 
minimum of 66% of participants from round 1 completing the process. 
 In round 5, the Panel were asked to vote again on statements from round 4 for 
which consensus was not reached, taking the results into consideration. 
Those who did not agree with the statements were asked to give reasons. 
 The Reviewing Group were asked to review the statements and vote regarding the 
ambition of each using a three-point scale (not ambitious enough, about right or 
too ambitious).
Results 
Defining a good standard of care
 For all 21 principles, over 75% of the 27 Panel members agreed in round 1 that the 
principle was an appropriate and accurate description of a good standard. 
 Three statements gained 100% (27/27) agreement: 
‘Early discussion with patient about the aims of treatment’
‘Evaluation of suitability/eligibility for treatment shortly after MS diagnosis’
‘Regular review of the aims of treatment’.
Timings for key steps in the patient pathway
 Rounds 4 and 5 were completed by 21/27 (78%) of the Delphi Consensus Panel.
 Here, we present standards related to treatment decisions, monitoring and 
managing new symptoms, which the Panel agreed should be achievable (Figure 2). 
Using standards to improve care 
Our vision 
 The quality standards from the Delphi process will be used as the basis of practical 
tools to support the implementation of recommendations from Brain health: time 
matters in multiple sclerosis.3 
 Established and developing MS clinics in different countries will be encouraged  
to compare their services to the core, achievable or aspirational standards, 
as appropriate.   
Quality improvement tool for clinics 
 An MS Brain Health quality improvement tool is proposed that will help MS clinics 
strive for the best possible standard of patient care (Figure 3).
 Leading MS specialist neurologists will be part of a collaborative effort to design 
the tool and pilot it in their clinics. 
Tool to empower people with MS 
 Resources for people with MS will be developed in close consultation with 
representatives from patient organizations (Figure 4). 
 We will explore whether it would be possible to collect information on what 
patients actually experience and provide feedback to participating clinics. 
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Rounds 4 and 5 – consensus statements
 In round 4, the Panel voted on the consensus statements, indicating agreement 
(or otherwise) on a five-point scale.
